The US Health and Human Services agency isn’t ready to go all in on “pull” incentives to encourage the development of new antibiotics, the agency indicated in response to a new Government Accountability Office report.
“It is still unclear whether post-market... Read more »
Some patients with a deadly type of tumor that forms in the gastrointestinal tract don’t respond to existing targeted therapies. On Friday the FDA approved Deciphera Pharmaceuticals drug ripretinib (Qinlock), a new treatment intended for patients with a gastrointestinal stromal tumor... Read more »
ADC Therapeutics is making its public markets debut, raising about $233 million six months after the cancer drug developer withdrew its initial IPO plans.
Not only did Épalinges, Switzerland-based ADC go through with the stock offering this time around, it... Read more »
This was a disappointing week for at least two major drug makers. French firm Genfit reported a trial failure in an intensely competitive indication, and New York-based Bristol Myers Squibb encountered a delay when the FDA declined to review its experimental... Read more »
Legend Biotech, a cancer cell therapy developer with roots in China, is preparing for a US stock exchange listing as its lead candidate keeps pace in the race for a multiple myeloma drug that addresses a new molecular target.
The drug,... Read more »
It may seem like an unlikely link but the body’s response to arthritis may hold answers for better cancer drugs, says Luis Voloch, chief technology officer of startup Immunai. Immune cells respond to both conditions, but in different ways. Insights into... Read more »
Two preclinical programs developed by Canadian biotech Northern Biologics have been acquired by privately held German company Boehringer Ingelheim, which is looking to bolster its cancer immunology portfolio.
The assets acquired from Northern Biologics in the deal, announced Thursday, are designed... Read more »
Bristol Myers Squibb’s bid to win FDA approval for its multiple myeloma cell therapy has hit a detour. The FDA declined to review the experimental treatment and has instead asked the company to provide more information.
Bristol (NYSE: BMY) announced... Read more »
Few drugs exist that treat amyotrophic lateral sclerosis, a progressive disease that kills the nerve cells that allow patients to initiate and control muscle movement.
QurAlis, a Cambridge, MA-based startup, has an ambitious plan to develop a number of “precision” therapies... Read more »